Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bibiana Bielekova

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Cold Spring Harbor Perspectives in Medicine|April 18, 2018
Daclizumab Therapy for Multiple SclerosisBibiana Bielekova
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 12, 2012
Daclizumab therapy for multiple sclerosisBibiana Bielekova
Brain : a Journal of Neurology|June 8, 2004
Development of biomarkers in multiple sclerosisBibiana Bielekova, Roland Martin
Annals of Neurology|January 26, 2012
Comment on "Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation"Bibiana Bielekova, Henry McFarland
Neurology|October 14, 2016
Sustained reduction of MS disability: New player in comparing disease-modifying treatmentsBibiana Bielekova, Mar Tintore
Neurology|March 27, 2015
Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?Bibiana Bielekova, Michael P McDermott
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 9, 2007
Emerging therapies for multiple sclerosisPaolo A Muraro, Bibiana Bielekova
Seminars in Pediatric Neurology|November 7, 2017
Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid ImmunophenotypingBibiana Bielekova, Michael R Pranzatelli
Neurology|December 30, 2009
Monoclonal antibodies in MS: mechanisms of actionBibiana Bielekova, Brenda L Becker
Frontiers in Neurology|December 2, 2024
Smartphone tests quantify lower extremities dysfunction in multiple sclerosisKimberly Jin, Peter Kosa, Bibiana Bielekova
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Cold Spring Harbor Perspectives in Medicine|April 18, 2018
Daclizumab Therapy for Multiple SclerosisBibiana Bielekova
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 12, 2012
Daclizumab therapy for multiple sclerosisBibiana Bielekova
Brain : a Journal of Neurology|June 8, 2004
Development of biomarkers in multiple sclerosisBibiana Bielekova, Roland Martin
Annals of Neurology|January 26, 2012
Comment on "Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation"Bibiana Bielekova, Henry McFarland
Neurology|October 14, 2016
Sustained reduction of MS disability: New player in comparing disease-modifying treatmentsBibiana Bielekova, Mar Tintore
Neurology|March 27, 2015
Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?Bibiana Bielekova, Michael P McDermott
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 9, 2007
Emerging therapies for multiple sclerosisPaolo A Muraro, Bibiana Bielekova
Seminars in Pediatric Neurology|November 7, 2017
Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid ImmunophenotypingBibiana Bielekova, Michael R Pranzatelli
Neurology|December 30, 2009
Monoclonal antibodies in MS: mechanisms of actionBibiana Bielekova, Brenda L Becker
Frontiers in Neurology|December 2, 2024
Smartphone tests quantify lower extremities dysfunction in multiple sclerosisKimberly Jin, Peter Kosa, Bibiana Bielekova
Pageof 10